- Home
- NTRA
NTRA
Natera Inc.
as 09-06-2024 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 13.7B | IPO Year: | 2015 |
| Target Price: | $123.64 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.90 - $124.83 | Next Earning Date: | 08-08-2024 |
| Revenue: | $1,360,503,000 | Revenue Growth: | 46.13% |
| Revenue Growth (this year): | 42.99% | Revenue Growth (next year): | 13.11% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sheena Jonathan | NTRA | Director | Aug 15 '24 | Sell | $121.01 | 12,000 | $1,452,124.80 | 287,441 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Aug 15 '24 | Sell | $119.39 | 5,583 | $663,895.23 | 200,710 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Aug 12 '24 | Sell | $116.67 | 3,956 | $461,546.52 | 114,606 | |
| Sheena Jonathan | NTRA | Director | Aug 12 '24 | Sell | $114.42 | 2,700 | $307,313.69 | 287,441 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Jul 29 '24 | Sell | $102.77 | 1,196 | $122,907.78 | 112,441 | |
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jul 29 '24 | Sell | $102.77 | 1,057 | $108,623.34 | 206,400 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Jul 29 '24 | Sell | $102.77 | 929 | $95,469.34 | 114,606 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jul 29 '24 | Sell | $101.21 | 3,104 | $313,170.84 | 71,955 | |
| Chapman Steven Leonard | NTRA | CEO AND PRESIDENT | Jul 29 '24 | Sell | $102.77 | 4,084 | $419,695.12 | 200,710 | |
| Brophy Michael Burkes | NTRA | CHIEF FINANCIAL OFFICER | Jul 24 '24 | Sell | $104.33 | 2,359 | $246,263.82 | 71,955 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
What Makes Natera (NTRA) an Investment Bet?
Insider Monkey
5 days ago
Natera (NTRA) Rose After Revenues And Profit Margins Beat Estimates
Insider Monkey
7 days ago
Billionaire Stan Druckenmiller Is Betting On Natera, Inc. (NTRA)
Business Wire
10 days ago
Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Simply Wall St.
11 days ago
Exploring Three High Growth Tech Stocks in the United States
Insider Monkey
11 days ago
PepsiCo, Inc. (PEP): Among Morgan Stanley’s Highest Conviction Stocks
Insider Monkey
11 days ago
Natera, Inc. (NTRA): Among Morgan Stanley’s Highest Conviction Stocks
GuruFocus.com
22 days ago
Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA)
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.